Anti-Saccharomyces cerevisiae antibodies (ASCA) in Behçet's syndrome

Clinical and Experimental Rheumatology

Volumn 23, Issue 4 SUPPL 38, 2005, Pages

  Fresko, Izzet ^a   Ugurlu, Serdal ^a   Ozbakir, Fatma ^a   Celik, Aykut ^a   Yurdakul, Sebahattin ^a   Hamuryudan, Vedat ^a   Yazici, Hasan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Antibody; ASCA; Beh et; Gastrointestinal

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN A ANTISACCHAROMYCES CEREVISIAE ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G ANTISACCHAROMYCES CEREVISIAE ANTIBODY; UNCLASSIFIED DRUG; FUNGUS ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ADULT; ANALYSIS OF VARIANCE; ANKYLOSING SPONDYLITIS; ARTICLE; BEHCET DISEASE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; TREND STUDY; ULCERATIVE COLITIS; YOUNG ADULT; BLOOD; GASTROINTESTINAL DISEASE; IMMUNOLOGY; MICROBIOLOGY; PATHOLOGY; SACCHAROMYCES CEREVISIAE;

ADULT; ANTIBODIES, FUNGAL; BEHCET SYNDROME; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; SACCHAROMYCES CEREVISIAE; SPONDYLITIS, ANKYLOSING;

EID: 33644811761     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. PEETERS M, JOOSSENS S, VERMEIRE S, VLIETINCK R, BOSSUYT X, RUTGEERTS P: Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-4.
2. KIM JE, KIM KS, SEO JK: Diagnostic role of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in pediatric inflammatory bowel disease. Korean J Gastroenterol 2003; 42: 297-302.
3. NIELSEN OH, VAINER B, MADSEN SM, SEIDELIN JB, HEEGAARD NH: Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol 2000; 95: 359-67.
4. GLAS J, TOROK HP, VILSMAIER F, HERBINGER KH, HOELSCHER M, FOLWACZNY C: Anti-saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease and their first-degree relatives: Potential clinical value. Digestion 2002; 66: 173-7.
5. YURDAKUL S, TUZUNER N, YURDAKUL I, HAMURYUDAN V, YAZICI H: Gastrointestinal involvement in Behçet's syndrome: A controlled study. Ann Rheum Dis 1996; 55: 208-10.
6. LEE CR, KIM WH, CHO YS et al.: Colonoscopic findings in intestinal Behçet's disease. Inflamm Bowel Dis 2001; 7: 243-9.
7. KORMAN U, CANTASDEMIR M, KURUGOGLU S et al.: Enteroclysis findings of intestinal Behçet disease: A comparative study with Crohn disease. Abdom Imaging 2003; 28: 308-12.
8. KRAUSE I, MONSELISE Y, MILO G, WEINBERGER A: Anti-Saccharomyces cerevisiae antibodies - A novel serologic marker for Behçet's disease. Clin Exp Rheumatol 2002; 20(Suppl 26): S21-4.
9. CHARUEL JL, DIEMERT MJ, MUSSET L, WECHSLER B, PIETTE JC: Abscence of anti-saccharomyces cerevisiae antibodies (ASCA) in BD. Book of Abstracts. 10th International Congress on Behçet's Disease. Berlin, 2002: Abstract 152.
10. CRITERIA FOR DIAGNOSIS OF BEHCET'S DISEASE; International Study Group for Behçet's Disease. Lancet 1990: 5; 335: 1078-1080.
11. YAZICI H, TUZUN Y, PAZARLI H et al.: Influence of age of onset and patient's sex on the prevalence and severity of Behçet's syndrome. Ann Rheum Dis 1984; 43: 783-9.
12. KIM BG, KIM YS, KIM JS, JUNG HC, SONG IS: Diagnostic role of anti- Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic antibodies in patients with inflammatory bowel disease. Dis Colon Rectum 2002; 45: 1062-9.
13. HAMZA M, AYED K, MAKNI S: Acquired and transitory selective IgA deficiency in Behçet's disease. Clin Exp Rheumatol 1991; 9: 208-9.
14. KLEBL FH, BATAILLE F, BERTEA CR et al.: Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease. Inflamm Bowel Dis 2003;9:302-7.
15. TEML A, KRATZER V, SCHNEIDER B et al.: Anti-Saccharomyces cerevisiae antibodies: A stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Am J Gastroenterol 2003; 98: 2226-31.